News + Resources
Keep up with the latest
Featured
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
CRISPR 2.0, the Next Generation
June 21, 2024
Aspen Ideas: Health
CRISPR 2.0, the Next Generation
June 21, 2024
All Stories
News
Sanofi, Doudna-founded Scribe Therapeutics to target sickle cell disease in new pact
July 17, 2023
Endpoints News
Read Now
Press Release
Sanofi, Doudna-founded Scribe Therapeutics to target sickle cell disease in new pact
July 17, 2023
Endpoints News
Read Now
News
Sanofi and Scribe’s expanded deal builds path to in vivo editing in SCD
July 17, 2023
BioCentury
Read Now
Press Release
Sanofi and Scribe’s expanded deal builds path to in vivo editing in SCD
July 17, 2023
BioCentury
Read Now
News
Sanofi goes back to Scribe
July 17, 2023
Evaluate
Read Now
Press Release
Sanofi goes back to Scribe
July 17, 2023
Evaluate
Read Now
News
Sanofi expands research deal with gene editing startup Scribe
July 17, 2023
Biopharma Dive
Read Now
Press Release
Sanofi expands research deal with gene editing startup Scribe
July 17, 2023
Biopharma Dive
Read Now
News
Scribe Therapeutics to Participate in Upcoming Investor Conferences in May and June
May 22, 2023
Read Now
Press Release
Scribe Therapeutics to Participate in Upcoming Investor Conferences in May and June
May 22, 2023
Read Now
News
Scribe Therapeutics Presents Data on its X-Editing Technologies at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 19, 2023
Read Now
Press Release
Scribe Therapeutics Presents Data on its X-Editing Technologies at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 19, 2023
Read Now